Pionering whole genome sequencing based genotoxicity testing

GlycoCheck measures and analyzes microvascular health, and objectively reports a MicroVascular Health Score (MVHS)

A robust patient monitoring device which is highly reliable and easy to use to prevent children in low and middle income countries unnecessary dying from severe bacterial infections.

HeartSmart revolutionizes cardiac research with a miniaturized heart tissue model that accurately mimics fibrosis and enables reliable, predictive drug testing for heart failure therapies.

HELIA Biomonitoring’s mission is to enable continuous monitoring of therapeutic drug concentrations, organ function markers, and treatment response markers for personalized patient care.

Liver toxicity is the main safety reason for drug attrition in clinical trials, causing 1 in every 13 drugs to fail. We have developed a novel, human liver model in a dish called hello which accurately predicts the toxicity of drugs.

A medical device for standardised capillary blood sampling without trained personnel, integrated into routine hospital and laboratory workflows.

the HUB provides access to a unique and robust platform that links patient-specific genetic and phenotypic information to preclinical and clinical drug-responsiveness.

Hy2Care develops a so called “injectable plaster” to repair the cartilage surface.

At Hybridize, we have developed a cost-effective proprietary therapeutic compound that can be intravenously administered to protect the kidney from BKV-mediated damage while maintaining full immunosuppression.